Capricor Therapeutics (CAPR) Total Current Liabilities (2010 - 2026)

Capricor Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $33.6 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 50.59% year-over-year to $33.6 million in Q1 2026; TTM through Mar 2026 was $33.6 million, a 50.59% increase from a year earlier, with the FY2025 full-year figure at $35.8 million, up 70.44% from the prior year.
• Total Current Liabilities declined to $33.6 million in Q1 2026 per CAPR's latest filing, from $35.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $37.1 million in Q1 2023 and bottomed at $14.3 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $26.4 million (2024), against an average of $26.8 million.
• Across the five-year window, Total Current Liabilities jumped 676.18% in 2022 and plunged 37.81% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $23.6 million in 2022, then jumped by 32.57% to $31.3 million in 2023, then tumbled by 32.76% to $21.0 million in 2024, then surged by 70.44% to $35.8 million in 2025, then declined by 6.14% to $33.6 million in 2026.
• Per Business Quant, the three latest CAPR Total Current Liabilities figures stand at $33.6 million (Q1 2026), $35.8 million (Q4 2025), and $28.1 million (Q3 2025).